Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature

Casirivimab and imdevimab (REGN-COV-2) are investigational monoclonal antibodies approved in November 2020 by the Food and Drug Administration for emergency use in mild and moderate COVID-19. These two noncompeting human IgG1 monoclonal antibodies can target the receptor-binding domain of the spike...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Reka Gabriela, Pawlak Angelika, Machowiec Piotr, Maksymowicz Marcela, Piecewicz-Szczesna Halina
Formato:	article
Lenguaje:	EN
Publicado:	Sciendo 2021
Materias:	covid-19 regn-cov-2 casirivimab imdevimab monoclonal antibodies Medicine R
Acceso en línea:	https://doaj.org/article/8d36b220768b4d5a88654c0f351f3369
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8d36b220768b4d5a88654c0f351f3369
record_format	dspace
spelling	oai:doaj.org-article:8d36b220768b4d5a88654c0f351f33692021-12-05T14:11:06ZCasirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature2300-667610.2478/cipms-2021-0030https://doaj.org/article/8d36b220768b4d5a88654c0f351f33692021-09-01T00:00:00Zhttps://doi.org/10.2478/cipms-2021-0030https://doaj.org/toc/2300-6676Casirivimab and imdevimab (REGN-COV-2) are investigational monoclonal antibodies approved in November 2020 by the Food and Drug Administration for emergency use in mild and moderate COVID-19. These two noncompeting human IgG1 monoclonal antibodies can target the receptor-binding domain of the spike protein of SARSCoV-2, prevent its entry into human cells, and reduce viral load. The antibodies can be administered intravenously for mild-to-moderate COVID-19 patients who do not require hospitalization and supplemental oxygen. The purpose of the study is to review the latest available data on COVID-19 treatment using casirivimab and imdevimab. According to recent preclinical studies, the antibody cocktail presents optimal antiviral strength and has the potential to minimize the chances of the virus escaping. It was shown in animal studies that the cocktail reduces the pathological consequences caused by viruses, decreases the number of viruses in the respiratory system, and reduces lung titers and pneumonia symptoms. Casirivimab and imdevimab as a cocktail also prevents the rapid appearance of treatment-resistant mutants. In the clinical trial, REGN-COV-2 decreased viral load, particularly in patients with a non-initiated immune response (serum antibody-negative) and with high viral load at baseline. The adverse effects were comparable in the combined REGN-COV2 dose groups (2.4 g and 8.0 g), as well as in the placebo group. The cocktail caused few and mainly low-grade toxic effects. Casirivimab and imdevimab seem to be effective and safe antiviral therapy for nonhospitalized patients with COVID-19. Further observations and research are extremely necessary to assess the efficacy, security and indications in a wider group of patients.Reka GabrielaPawlak AngelikaMachowiec PiotrMaksymowicz MarcelaPiecewicz-Szczesna HalinaSciendoarticlecovid-19regn-cov-2casirivimabimdevimabmonoclonal antibodiesMedicineRENCurrent Issues in Pharmacy and Medical Sciences, Vol 34, Iss 3, Pp 138-141 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	covid-19 regn-cov-2 casirivimab imdevimab monoclonal antibodies Medicine R
spellingShingle	covid-19 regn-cov-2 casirivimab imdevimab monoclonal antibodies Medicine R Reka Gabriela Pawlak Angelika Machowiec Piotr Maksymowicz Marcela Piecewicz-Szczesna Halina Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature
description	Casirivimab and imdevimab (REGN-COV-2) are investigational monoclonal antibodies approved in November 2020 by the Food and Drug Administration for emergency use in mild and moderate COVID-19. These two noncompeting human IgG1 monoclonal antibodies can target the receptor-binding domain of the spike protein of SARSCoV-2, prevent its entry into human cells, and reduce viral load. The antibodies can be administered intravenously for mild-to-moderate COVID-19 patients who do not require hospitalization and supplemental oxygen. The purpose of the study is to review the latest available data on COVID-19 treatment using casirivimab and imdevimab. According to recent preclinical studies, the antibody cocktail presents optimal antiviral strength and has the potential to minimize the chances of the virus escaping. It was shown in animal studies that the cocktail reduces the pathological consequences caused by viruses, decreases the number of viruses in the respiratory system, and reduces lung titers and pneumonia symptoms. Casirivimab and imdevimab as a cocktail also prevents the rapid appearance of treatment-resistant mutants. In the clinical trial, REGN-COV-2 decreased viral load, particularly in patients with a non-initiated immune response (serum antibody-negative) and with high viral load at baseline. The adverse effects were comparable in the combined REGN-COV2 dose groups (2.4 g and 8.0 g), as well as in the placebo group. The cocktail caused few and mainly low-grade toxic effects. Casirivimab and imdevimab seem to be effective and safe antiviral therapy for nonhospitalized patients with COVID-19. Further observations and research are extremely necessary to assess the efficacy, security and indications in a wider group of patients.
format	article
author	Reka Gabriela Pawlak Angelika Machowiec Piotr Maksymowicz Marcela Piecewicz-Szczesna Halina
author_facet	Reka Gabriela Pawlak Angelika Machowiec Piotr Maksymowicz Marcela Piecewicz-Szczesna Halina
author_sort	Reka Gabriela
title	Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature
title_short	Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature
title_full	Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature
title_fullStr	Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature
title_full_unstemmed	Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature
title_sort	casirivimab and imdevimab as investigational monoclonal antibodies for covid-19 patients – review of the literature
publisher	Sciendo
publishDate	2021
url	https://doaj.org/article/8d36b220768b4d5a88654c0f351f3369
work_keys_str_mv	AT rekagabriela casirivimabandimdevimabasinvestigationalmonoclonalantibodiesforcovid19patientsreviewoftheliterature AT pawlakangelika casirivimabandimdevimabasinvestigationalmonoclonalantibodiesforcovid19patientsreviewoftheliterature AT machowiecpiotr casirivimabandimdevimabasinvestigationalmonoclonalantibodiesforcovid19patientsreviewoftheliterature AT maksymowiczmarcela casirivimabandimdevimabasinvestigationalmonoclonalantibodiesforcovid19patientsreviewoftheliterature AT piecewiczszczesnahalina casirivimabandimdevimabasinvestigationalmonoclonalantibodiesforcovid19patientsreviewoftheliterature
_version_	1718371371201855488

Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature

Ejemplares similares